Good morning ... Summer's hottest action movie is this surveillance footage from a Canadian convenience store. Hollywood is wasting its money trying to compete.
Kentucky Gov. Matt Bevin (left) and President Trump. Photo: Mark Wilson/Getty Images
Republican governors and the Trump administration both suffered a serious setback on Friday when a federal judge blocked Kentucky's version of Medicaid work requirements from taking effect.
Why it matters: Work requirements are among the most significant changes the Trump administration has made so far in health policy. The new rules are also a critical part of conservatives' effort to frame Medicaid as a welfare program.
The catch: That's exactly why the policy ran into trouble in court.
Driving the news: U.S. District Judge James Boasberg ruled Friday that the Health and Human Services Department had not sufficiently demonstrated that work requirements would further Medicaid's goals as a health care program.
What to watch: Boasberg's ruling only applies to Kentucky, not the other states where HHS has approved work requirements. But this will not be the last legal challenge, and if more judges follow Boasberg's lead, the administration's effort to redefine Medicaid could end up backfiring.
The Trump administration is considering even more cuts to Affordable Care Act enrollment outreach, The Hill reports.
Between the lines: ACA enrollment dipped only slightly this year despite the cut to navigator funding, which was only part of a broader rollback of federal outreach efforts.
Emergency rooms are facing severe shortages of commonly used drugs, in part because of problems at Pfizer plants, The New York Times reports.
The details: Shortages of pain medications like morphine are especially severe.
The issue: These drugs' low profit margins are part of the reason more companies don't manufacture them, FDA Commissioner Scott Gottlieb told the Times.
Health and Human Services Secretary Alex Azar has said a couple of times now that some drug companies wanted to voluntarily lower their prices, but have faced resistance from pharmacy benefit managers.
The big question: Democratic Sens. Elizabeth Warren and Tina Smith want to know whether that’s true.
The latest: Warren and Smith sent letters late last week to nine PBMs and drug distributors, asking them whether any drugmakers have tried to pursue price cuts, and how they responded.
What they’re saying: “If they are true, these allegations suggest that PBMs and drug distributors are acting to maintain high list prices in order to maintain high profit margins, potentially raising antitrust concerns,” the letters state.
Go deeper: How PBMs can benefit from high list prices.
What we're watching this week: Congress is out, so the agenda here in Washington is looking pretty light.
Let me know what you're watching: email@example.com.